NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015

Go back to NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015
NEOGENOMICS (NASDAQ: NEO) Delayed: 17.38 --0 (-0%)
Previous Close $17.38    52 Week High $9.54 
Open $17.38    52 Week Low $5.49 
Day High $17.38    P/E 434.50 
Day Low $17.38    EPS $0.04 
Volume 3,507